

07-07-00

Customer No. 000959

Case Docket No. CGR-013CP2

THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application

Washington, D.C. 20231

JC845 U.S. PTO
07/06/00JC857 U.S. PTO
09/06/00
09/610281

"Express Mail" Mailing Label Number EL 373 207 525 US

Date of Deposit July 6, 2000

I hereby certify that this transmittal letter and the papers referred to as being enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Signature

Nelson Barros

Please Print Name of Person Signing

Sir:

Transmitted herewith for filing is the continuation-in-part patent application under 37 CFR §1.53 of pending prior patent application **Serial No. 09/315,480** filed May 20, 1999 entitled **"Adhesive N,O-Carboxymethylchitosan Coatings Which Inhibit Attachment of Substrate-Dependent Cells and Proteins"**.

Inventors: Clive M. Elson and Agis Kydonieus

For: *Adherent N,O- Carboxymethylchitosan Drug Delivery Devices for Moist Tissue and Methods of Their Use*

Enclosed are:

- ☒ 24 pages of specification, 3 pages of claims, 1 page of abstract;
- ☒ 8 sheets of informal drawings (Figures 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10);
- ☒ An *unexecuted* Declaration, Petition and Power of Attorney;
- ☒ A pre-paid acknowledgment postcard.

The filing fee has been calculated as shown below:

	(Col. 1)	(Col. 2)
FOR:	NO. FILED	NO. EXTRA
BASIC FEE	////////////////////	
TOTAL CLAIMS	26 - 20	= 6
INDEP. CLAIMS	3 - 3	= 0
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED		

* If the difference in Col. 2 is less than zero, enter "0" in Col. 2.

SMALL ENTITY	
RATE	FEE
////////	\$
x 9=	\$
x 39	\$
+130	\$
TOTAL	0

OTHER THAN SMALL ENTITY	
RATE	FEE
////////	\$ 690
x 18=	\$ 108
x 78	\$ 0
+260	\$
TOTAL	\$798.00

- ☒ A check in the amount of **\$798.00** to cover the filing fee is enclosed.
- ☐ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 12-0080.

09/06/00 09/06/00 09/06/00

- Lahive & Cockfield, LLP**
28 State Street
Boston, Massachusetts 02109

By:

Facsimile: (617) 742-4214

ADHERENT N,O-CARBOXYMETHYLCHITOSAN DRUG DELIVERY DEVICES FOR MOIST TISSUE AND METHODS OF THEIR USE

Reference to Related Applications

5 This application is a continuation-in-part of United States Patent Application
Serial No. 09/315,480, entitled "ADHESIVE N,O-CARBOXYMETHYLCHITOSAN
COATINGS WHICH INHIBIT ATTACHMENT OF SUBSTRATE-DEPENDENT
CELLS AND PROTEINS," filed May 20, 1999, the disclosure of which is incorporated
herein by reference.

10

Background of the Invention

 A variety of drug delivery devices are known in the art. These include implants,
various polymers, microcapsules, liposomes, stents and many hybrids devices. While
these drug delivery devices work well in certain body locations, such as skin or muscle
15 tissue, they often fail to work in moist tissue locations. In moist tissue, such as mucosal
membranes or tissue in the serous cavities, there is a problem keeping the drug delivery
device in place for a sufficiently long time to provide the requisite delivery of the drug at
the proper site. While physical methods of keeping the drug delivery device at the
proper site, such as the use of sutures have been tried, there may still be problems with
20 controlling the delivery rate or biocompatibility. Accordingly, it has been theorized that
an adherent drug delivery device might provide certain benefits.

 Various bioadhesives are known in the art. U.S. Pat. No. 4,615,697, issued to
Robinson et al., defines a bioadhesive as a material that requires a force of at least about
25 50 dynes/cm² to separate two adhered, freshly excised pieces of rabbit stomach,
following the procedure disclosed therein. The bioadhesive disclosed in Robinson et al.
is a water-swellaable, but water insoluble, fibrous, cross-linked carboxy-functional
polymer.

30 The bioadhesives described in the Robinson patent actually show cohesive
failure rather than adhesive failure (*see* Example 1 above). In contrast, the use of NOCC
as the bioadhesive in the drug delivery device allows one to tailor the device such that
failure of breakaway from tissue can be controlled to be either adhesive or cohesive as
desired. In addition, biocompatibility is improved where desired. These devices can
35 also be tailored to provide sustained release of drugs in a controlled manner. In addition,
Robinson's polymers are not bioresorbable.

Accordingly, it is an object of the invention to provide new adherent devices and methods of drug delivery to moist tissue.

Another object of the invention is to provide adherent drug delivery devices for
5 use with moist tissue that can be tailored in terms of delivery time and compatibility through the use of additional structural materials.

A further object of the invention is to provide an adherent drug delivery device and methods of their use for buccal, eye, vaginal, gastrointestinal, or intra-serous cavity
10 drug delivery.

A still further object of the invention is to provide an adherent coating that helps prevent the formation of surgical adhesions.

15 An additional object of the invention is to provide an adherent coating that helps seal tissue.

These and other objects and features of the invention will be apparent from the detailed description and the claims.
20

Summary of the Invention

The present invention features a method of utilizing an adherent form of N,O-carboxymethylchitosan ("NOCC") to deliver a series of materials to tissue. The invention is based, in part, on the discovery of adherent coatings of NOCC may be
25 applied to various substrates, such as mammalian tissue, so as to allow delivery of materials such as drugs or hormones to the specific site.

The present invention provides a series of compositions that is adherent to a variety of synthetic materials and mammalian tissues. These compositions can be used
30 as a device for vaginal delivery of hormones, as buccal implants, as eye implants or drug delivery devices and the like for localized or systemic delivery of a variety of materials when adhered to the delivery site.

In one embodiment, the invention provides a composition and method of
35 delivering drugs, proteins, and other therapeutic agents from an adhesive device or composition that is adherent to soft (mucosal or non-mucosal) tissue or hard tissue. In preferred embodiments, the adherent delivery device can be used as a buccal, oral,

vaginal, inhalant, or the like delivery system. The device can be in a variety of forms including solutions, creams, pellets, particles, beads, gels, and pastes. In some embodiments, the NOCC is supplemented with a structural support material selected from the group consisting of rubber, plastic, resin, natural and synthetic polymers, and mixtures thereof.

The method is useful for providing sustained release of a drug to moist tissue. The method uses the steps of applying to said moist tissue a drug delivery device which is adherent to said moist tissue and includes a level of N,O-carboxymethylchitosan as a component thereof to provide said adherence. The drug delivery device further containing a sufficient quantity of the drug to be delivered to provide sustained release of said drug and permeation into said moist tissue. The preferred moist tissues are mucosal tissue and tissue within serous cavities. Preferred mucosal tissue is tissue of the oral cavity such as buccal tissue, vaginal tissue, ocular tissue, and gastrointestinal tissue. Preferred tissues within a serous cavity are tissues within the pleural, pericardial or peritoneal cavities.

The method is useful for delivering a number of drugs such as chlorhexidine, tetracycline and mixtures thereof for treatment of buccal problems like mouth sores and periodontal disease or drugs such as melatonin and chlorpheniramine through the buccal mucosa for systemic therapy. The method can also be used to deliver drugs to the vaginal tissue like progestins, estrogens, antifungal agents, antibacterial agents, anti-viral agents, proteins and peptides, particularly levonorgestrel. Similarly, the method can be used to deliver drugs to ocular tissue such as beta blockers and glaucoma treating drugs.

The method of the invention may also provide for adherence or sealing of tissue and prevention of post-surgical adhesions. This method utilizes a medical device that includes NOCC and optionally, a tissue sealant such as a fibrin sealant or a cyanoacrylate. In this case, the preferred moist tissue is at the site of a surgical incision. The primary tissues to be sealed are lung tissues, heart tissues and intestinal tissue.

Brief Description of the Drawings

FIG. 1 is a schematic of the apparatus used in Example 1.

FIG. 2 is a bar graph showing the results of Example 1.

FIG. 3 is a schematic of the procedure used in Example 2.

FIG. 4 is graph showing the total volume of ^{125}I -NOCC adhered to rat femur, as calculated using Equation 1.

5

FIG. 5 is graph showing the total volume of ^{125}I -NOCC adhered to rat femur, as calculated using Equation 3.

FIG. 6 is a graph showing the *in vitro* permeation of levonorgestrel from a vaginal cream in a diffusion test chamber.

10

FIG. 7 is a graph showing the *in vitro* permeation of melatonin from a buccal device in a diffusion test chamber.

FIG. 8 is a graph showing the permeation of chlorpheniramine maleate from a buccal device in a diffusion test chamber.

15

FIG. 9 is a graph showing the permeation of chlorhexidine diacetate from a buccal device in a diffusion test chamber.

20

FIG. 10 is a graph showing the permeation of timolol maleate from an eye delivery device using a diffusion test chamber.

Detailed Description of the Invention

The present invention relates to the delivery of a variety of drugs, hormones and the like through the use of a site adherent delivery device. The method of the invention uses an adherent coating of N,O-carboxymethylchitosan ("NOCC") that provides unexpected benefit.

NOCC is a derivative of chitin, which is found in the shells of crustaceans and many insects. Chitin and its derivatives are normally biocompatible, naturally resorbed by the body, and have previously been suggested for use for sustained drug release, bone induction and hemostasis (Chandy and Sharma, *Biomat. Art. Cells & Immob. Biotech.* 19:745-760 (1991); Klokkevold, P. *et al.*, *J. Oral Maxillofac. Sur.* 50:41-45 (1992)). Due to its prevalence, chitin may be obtained relatively cheaply, largely from waste products. One of the most useful of the chitin derivatives is NOCC. As disclosed in U.S. Pat. No. 4,619,995, issued to Hayes, the entire contents of which are hereby

30
35

incorporated by reference, NOCC has carboxymethyl substituents on some of both the amino and primary hydroxyl sites of the glucosamine units of the chitosan structure. NOCC may be used in an uncrosslinked form as a solution or may be cross-linked or complexed into a stable gel. Because of its advantageous physical properties, and its
5 relative low cost, NOCC presents advantageous properties for use in site localized delivery systems.

Definitions

10 The terms “adherent NOCC” or “an adherent coating of NOCC” mean a coating or composition of NOCC that exhibits an adhesion between freshly excised tissues of at least about 100 dynes/cm², using the procedure described in Example 1.

15 The term “medical device” means any device which is implanted in the body for medical reasons or which has a portion of the device extending into the body (like a catheter) as well as devices which provide a medical benefit when attached to, or are in contact with, the body. Examples of medical devices include, without limitation, hemostats, tissue sealants, and adhesion prevention barriers.

20 The term “delivery device” means any type of device that can be used to deliver the contained material at the localized site. The delivery device may be as simple as an adherent paste applied to the site or may be shaped or constructed for the particular application.

25 The term “drug” means any product which causes an effect in a cell or organism including, but not limited to classic drugs, peptides, proteins, antibodies and the like.

 The term “moist tissue” means a tissue that in its normal activity is kept moist. Moist tissue includes mucosal tissue and tissue in the serous cavities.

30 The adherent NOCC used in the present invention may take many forms. For example, adherent NOCC may be used in a solution, a hydrogel, a paste, a rehydratable film, cream, foam, or a sponge. These forms are prepared by methods well known to those of ordinary skill in the art. The delivery device may have other structural
35 materials as well as NOCC. Some of these include chitosan, carboxymethylcellulose, resins, alginate, rubbers and the like.

The adherent NOCC used in the present invention may be the parent compound or may be cross-linked. Cross-linked adherent NOCC may be either covalently cross-linked or ionically cross-linked. Various methods of cross-linking NOCC are known in the art and are within the scope of this invention. In addition, the degree to which the adherent NOCC is cross-linked may be optimized for specific applications by one of ordinary skill without undue experimentation. It has been found that the degree of cross-linking is roughly inversely proportional to the adhesiveness of the coating. That is, the greater the degree of cross-linking of the adherent NOCC, the lesser degree of adherence. In preferred embodiments, the degree of cross-linking is less than 1:5 (moles cross-linking agent to moles, NOCC monomer), more preferably between 1:100 and 1:1000 on a molar basis.

The bioadhesive strength of several adherent NOCCs was compared to that of polycarbophil, a cross-linked acrylic acid polymer available from B.F. Goodrich. As more fully described in Example 1, solutions of low and high viscosity NOCC were prepared, as well as hydrogels of high viscosity NOCC. The bioadhesive was applied to stomach and cecal tissue samples and the bioadhesive strength was measured according to a modified version of the procedure disclosed in U.S. Pat. No. 4,615,697, the disclosure of which is hereby incorporated by reference. The transfer of polymer to both tissue surfaces indicated that the adhesive force of the polymer exceeded the cohesive force. A summary of results appears in Tables 1 and 2, and Figure 2. In preferred embodiments, the bioadhesive strength of adhesive NOCC coatings of the invention is desirably greater than at least about 1000 dynes/cm², more preferably greater than at least about 2000 dynes/cm², and most preferably greater than at least about 3000 dynes/cm².

Both the low viscosity and high viscosity NOCC polymer solutions in citrate buffer behaved similarly to polycarbophil when applied as a coating to the mucosal surface of stomach tissue (Table 1). This was also true for similar solutions of NOCC using phosphate buffered saline instead of citrate buffer as well as non-mucosal, cecal tissue (Table 2). It was observed that as NOCC was cross-linked, the cohesion of the materials increased and the adhesion decreased. The loss of adhesion was dependent on the extent of cross-linking. These findings are likely attributable to the fact that cross-linking adherent NOCC introduced more structure into the polymer, which consequently restricted interactions with the tissue surface. The cross-linking also joined the polymer chains together, resulting in increased cohesiveness.

The ability of NOCC to adhere to bone tissue was also studied. The results indicate that NOCC adheres to bone tissue (Figure 5). After the third wash, $9.5 \times 10^{-3} \pm 0.002 \mu\text{L}/\text{mm}^2$ (or about $0.1 \mu\text{g NOCC}/\text{mm}^2$) of ^{125}I labeled NOCC remained adhered to the rat femur.

5

The following, non-limiting examples will further elucidate the invention.

Example 1

In this example, the bioadhesive strength of several adherent NOCC coating
 10 compositions is compared to that of polycarbophil. Polycarbophil (B.F. Goodrich, Akron, Ohio) was prepared as a 4% w/v solution in both 0.2M citrate buffer (pH 4.8) and 0.9% saline (pH 6.8). Low viscosity ("LV") NOCC (240 cps, Brookfield spindle 3, 50-100 rpm) was prepared as 4% w/v solution in citrate buffer (pH 5.6). High viscosity ("HV") NOCC (P78NOCC1) was prepared as 2.5% w/v solution in citrate buffer (pH
 15 5.6). High viscosity NOCC was prepared as 1% and 2.5 % in citrate buffer (pH 5.6-5.7), autoclaved and cross-linked (1:500). HV NOCC was also prepared as 2.5% solution in phosphate buffered saline (PBS). Gels were formed from 1% HV NOCC by cross-linking (1:100) in PBS and by cross-linking (1:250) in saline following autoclaving.

20 Both stomach and cecal tissues from Sprague-Dawley rats were harvested immediately prior to testing and were kept moist in saline solution. Tissue samples were mounted on circular plastic disks with the inner surfaces of stomach tissues and the outer surfaces of cecal tissues exposed. Tissue samples were held in place with a suture around the end of the plastic disks. The plastic disks were obtained from the plungers of
 25 3 and 5 ml syringes; the diameters of the disks were 7.0 (surface area of 38.5 mm^2) and 9.5 mm (surface area of 70.9 mm^2), respectively. The tissue holders were attached to a cantilever load cell and to the actuator of an MTS servohydraulic material testing machine (see Figure 1).

30 The temperature compensated load cell was wired into a Daytronic 3720 Strain Gauge Conditioning Unit in a half bridge configuration. Data collection was performed using a Macintosh Centris 650 computer equipped with labVIEW software and a 12-bit NB-MIO-16 data acquisition board. The cantilever load cell was calibrated over the working range of 0-3 grams using a series of proving masses (0.1, 0.23, 0.5, 1 to 3.0 g)
 35 verified on a Mettler PJ 360 balance. A least squares calibration curve was determined to convert the resulting output from volts to grams force.

The smaller diameter tissue of the pair of fresh tissue samples received 30 µl of test material. The software was designed to take a zero reading after attaching the tissue samples and applying a coating of the bioadhesive. The testing system actuator was then manually advanced using the displacement potentiometers to bring mating faces
5 into compression while visually monitoring the resulting load level on the computer monitor. The mating faces were allowed to remain compressed at a nominal load of 0.9 g for one minute. The computer then displaced the actuator at a constant rate of 12.0 mm/min, monitoring the distraction force with time. After failure the computer determined the peak distraction load and saved the loading curves to a spreadsheet file.

10 For repeated testing of the same samples, the tissues were scraped with the side of a syringe needle, rinsed with citrate buffer or water as appropriate and a new aliquot of the same polymer was applied. Fresh tissues were used for each different polymer sample; all samples in citrate buffer were tested on stomach tissue and all samples at
15 neutral pH were tested on cecal tissue. All testing was performed in air.

All polymer samples were applied to the smaller surface area tissue sample at a rate of approximately 1µl/mm². Following distraction of the actuator, the transfer of polymer to both tissue surfaces indicated that the adhesive force of the polymer
20 exceeded the cohesive force. For example, polycarbophil was adhesive to both cecal and stomach tissue and required a tensile force of 2300-2800 dynes/cm² to cause failure. The failure was cohesive rather than adhesive since polymer was observed on both tissue surfaces after separation. A summary of results appears in Tables 1 and 2 and Figure 2.

25 Both the low viscosity and high viscosity adherent NOCC polymer solutions in citrate buffer behaved similarly to polycarbophil when applied as a coating to the mucosal surface of stomach tissue. Both adherent NOCC samples failed cohesively and required larger forces to achieve tissue separation than for polycarbophil. However, when high viscosity NOCC solutions were cross-linked to form hydrogels, they became
30 more cohesive and failed by detaching from the larger diameter disk at forces of 85% (1% gel) and 53% (2.5% gel) of that of polycarbophil.

The strengths of adhesion to the external surface of the cecum (Table 2) again demonstrated that a solution of NOCC (2.5%-high viscosity) was comparable to
35 polycarbophil. It was also observed that as adherent NOCC was cross-linked the cohesion of the materials increased and the adhesion decreased. The loss of adhesion was dependent on the extent of cross-linking.

It should be noted that polycarbophil measured under the present conditions exhibited twice the adhesive force as reported in U.S. Pat. No. 4,615,697. This is presumably due to testing in air rather than in solution. For both stomach and cecal tissues, adherent NOCC solutions were either comparable to or exceeded the performance of polycarbophil: the force required to achieve failure was equal to or larger than that of polycarbophil and failure was due to cohesion not adhesion.

NOCC hydrogels on both types of tissue were adhesive; however, they were significantly less adhesive than materials that were not cross-linked. They demonstrated an adhesive failure rather than cohesive; also it was observed that increasing the extent of cross-linking decreased the adhesive force. These findings were not surprising since cross-linking adherent NOCC introduced more structure into the polymer, which restricted interactions with the tissue surface and also joined the polymer chains together resulting in increased cohesiveness.

Another finding was that both the 2.5 % high viscosity NOCC solution and the 1% NOCC gel in citrate were more adhesive than its counterparts in PBS. Without limitation to the present invention, this difference may possibly be explained by the influence of the citric acid environment. At neutral pH, NOCC exists as an anionic species resulting from the presence of negatively charged carboxyl ate groups (-COO⁻); the free amines on NOCC are primarily uncharged. By contrast, in acidic citrate buffer (pH 5.6) the amine groups are protonated to form positively charged ammonium sites (-NH₃⁺) that ionically bind citrate ions. Such salts are described in United States Patent No. 5,412,084, the disclosure of which is incorporated herein by reference. Since citrate has three carboxylate groups, two of which are negatively-charged at pH 5.6, the net result is that NOCC in acidic citrate has an increased number of carboxylate groups associated with the polymer and, hence, displays an increased bioadhesiveness.

Table 1. Bioadhesion of NOCC Formulations to Stomach Tissue.

<u>Polymer Sample</u>	<u>Tensile Failure Force (grams)</u>	<u>Force to Separate Tissue (dynes/sq.mm)</u>	<u>Adhesive or Cohesive Failure</u>
4% Polycarbophil	0.901±0.035	2295±170	Cohesive
4% LV NOCC solution	1.007±0.107	2567±270	Cohesive
2.5% NOCC (HV)	1.513	3857	Cohesive

1% NOCC gel	0.770±0.280	1961±410	Adhesive
2.5% NOCC gel	0.481	1226	Adhesive
Notes: Error limits are one average deviation based on 2-3 determination and values without error limits result from a single measurement.			

Table 2: Bioadhesion of NOCC Formulations to Cecal Tissue.

<u>Polymer Sample</u>	<u>Tensile Failure Force (grams)</u>	<u>Force to Separate Tissue (dynes/sq.mm)</u>	<u>Adhesive or Cohesive Failure</u>
4% Polycarbophil	1.113	2837	Cohesive
2.5% NOCC (HV) solution	0.992±0.060	2567±140	Cohesive
1% NOCC gel (1:100)	0.302±0.010	770±30	Adhesive
1% NOCC gel (1:250)	0.410	1045	Adhesive
Notes: Error limits are one average deviation based on 2-3 determination and values without error limits result from a single measurement.			

5

Example 2

This example illustrates the adherent property of an adherent NOCC coating of the present invention.

Six female rats were anaesthetized using sodium pentobarbital (60 mg/kg) and subsequently sacrificed by cervical dislocation. Twelve femurs were harvested and stripped of connective tissue by sharp dissection. Excess connective tissue was removed from the rat femur by immersing the rat femurs in boiling water for thirty minutes. The femurs were then rinsed and air dried.

Each femur was immersed in 1 ml of ¹²⁵I labeled NOCC such that half the surface area of the femur was in direct contact with the ¹²⁵I NOCC solution (Figure 3). The other half of the femur was used to manipulate the femur. Subsequently, the femur was either placed directly into a scintillation vial and then placed in a γ- counter rack, or the femur was subjected to a uniform "wash" before being placed into a scintillation vial and the γ- counter rack.

Four groups of three ¹²⁵I NOCC treated femurs were subjected to either one wash, two washes, three washes or no washes. A wash consisted of the uniform agitation of the femur in approximately 150 ml of PBS for five seconds. Two washes consisted of a wash, removing the femur from PBS for one second, and then repeating a wash. Hence, three washes consisted of a wash, removal of the femur, a wash, removal of the femur, and one last wash. The PBS solution was replaced for each group of femurs.

The activity of ¹²⁵I NOCC was evaluated by a Beckman γ-counter. The amount of ¹²⁵I NOCC adhered to a rat femur was calculated using Equation 1, which uses the activity of 1 ml of ¹²⁵I NOCC (7.2 x10⁷ CPM) and the activity of the ¹²⁵I NOCC on the femur, (detected by the γ- counter). The results appear in Figure 4.

Equation 1:

Volume of ¹²⁵I NOCC adhered to femur =

$$\frac{\text{Activity (CPM) of sample} \times 1 \text{ mL}}{7.2 \times 10^7 \text{ CPM}}$$

Next, the amount of ¹²⁵I NOCC per unit area of the femur was calculated. The surface area that was in direct contact with the ¹²⁵I NOCC solution was calculated for one representative rat femur.

Equation 2:

Surface area in direct contact with ¹²⁵I NOCC=

$$\frac{2\pi rh}{2} + \pi r^2$$

Where h = the total height of the femur; r = the radius of the femur

The amount of ¹²⁵I NOCC per unit area of then calculated, using Equation 3, by dividing the surface area of the rat femur in direct contact with ¹²⁵I NOCC into the amount of ¹²⁵I NOCC adhered to the rat femur. The results appear in Figure 5.

Equation 3:

¹²⁵I NOCC per unit area of femur =

$$\frac{\mu\text{L of } ^{125}\text{I NOCC adhered to femur}}{\text{Surface area in direct contact with } ^{125}\text{I NOCC}}$$

The surface area of the rat femur was calculated to be 228 mm², (radius = 2.25 mm and total femur height = 30 mm).

- 5 Table 3 outlines the number of washes each femur was subjected to, the activity of ¹²⁵I NOCC, amount of ¹²⁵I NOCC adhered to femur, and the amount of ¹²⁵I NOCC per unit area of femur.

Table 3: ¹²⁵I NOCC adhered to femur

10

Femur number	Number of washes/femur	Activity ¹²⁵ I NOCC/femur (CPM)	Volume of ¹²⁵ I NOCC adhered to femur (μL)	Volume of ¹²⁵ I NOCC (μL)/ unit area of femur (mm ²)
1	0	2.3 x 10 ⁶	31.9	1.4 x10 ⁻¹
2	0	2.7 x 10 ⁶	37.5	1.6 x10 ⁻¹
3	0	2.9 x 10 ⁶	40.3	1.8 x10 ⁻¹
4	1	6.9 x 10 ⁵	9.6	4.2 x10 ⁻²
5	1	5.1 x 10 ⁵	7.1	3.1 x10 ⁻²
6	1	3.9 x 10 ⁵	5.4	2.4 x10 ⁻²
7	2	1.4 x 10 ⁵	1.9	8.3 x10 ⁻³
8	2	1.4 x 10 ⁵	1.9	8.3 x10 ⁻³
9	2	2.9 x 10 ⁵	4.0	1.8 x10 ⁻²
10	3	1.6 x 10 ⁵	2.2	9.6 x10 ⁻³
11	3	1.3 x 10 ⁵	1.8	7.9 x10 ⁻³
12	3	1.8 x 10 ⁵	2.5	11.0 x10 ⁻³

The results indicate that ¹²⁵I NOCC adheres to rat femur. After a third wash, it was found that 9.5 x 10⁻³ +/- 0.002 μL/mm² (or about 0.1 μg NOCC/mm²) of ¹²⁵I NOCC remained adhered to the rat femur.

15

Example 3

In this example, a vaginal cream containing levonorgestrel, a steroid, was prepared. This cream is useful as an intravaginal delivery device.

20

The NOCC-based cream was prepared with the following composition:

1.56% N,O-Carboxymethylchitosan (NOCC)
3.1% heavy mineral oil
9.3% glycerol

1.5% SPAN 60 (sorbitan monostearate, Atkemix, Inc.)
0.30% levonorgestrel (Sigma Aldrich)
84.2% 36mM citrate buffer (pH 4.2)
(All percentages are weight to volume.)

5

The cream was prepared by dissolving solid NOCC in hot citrate buffer and adjusting the pH to 5 with citric acid. Separately, SPAN 60 was warmed and combined with mineral oil, the levonorgestrel was added, and finally the glycerol. The warm NOCC solution was then combined with the levonorgestrel mixture to form the cream.

10

The resulting cream was homogeneous, easily smeared, and adherent to tissue. The cream contained 3 mg levonorgestrel per gram.

Example 4

15 In this example, a spermicidal and anti-microbial cream containing Nonoxynol-9, a well known spermicide, was prepared. This cream is adherent to mucousal tissue such as vaginal tissue.

20

A NOCC-based cream was prepared with the following composition:

25

2.5% N,O-Carboxymethylchitosan (NOCC)
2.5% hydroxypropylmethyl cellulose (HPMC)
5% Nonoxynol-9
0.5% sodium dodecyl sulfate (SDS)
0.1% Antifoam A (Dow Corning)
89.4% 36mM citrate buffer (pH 4.2)
(All percentages are weight to volume.)

30 To prepare the cream, the Antifoam A and the Nonoxynol-9 were added to hot citrate buffer. The NOCC and the HPMC were combined in equal weights and then added to the warm citrate buffer mixture and blended. Finally, the solid SDS was combined to form a creamy paste.

The resulting cream was homogeneous, easily smeared, and adherent to tissue.

Example 5

In this example, a buccal device containing NOCC and other polymers was prepared. This device is useful as a buccal drug delivery device.

5

A PVC resin composition was made by diluting a high viscosity (polyvinyl chloride"PVC") resin (available from Plast-o-Meric, Inc) with dioctylphthalate in the ratio of two thirds resin to one third dioctylphthalate.

10

An alginate paste was prepared having the following composition:

15

55% sodium alginate
30% chitosan
15% PVC resin composition as shown above
(All percentages are weight to weight.)

20

A NOCC paste was also prepared having the following composition:

33% NOCC
33% chitosan
33% PVC resin composition
(All percentages are weight to weight.)

25

The buccal device was prepared by compressing 60 mg of the alginate paste in a hand-held potassium bromide pellet press (Barnes Analytical, Pellet Holder for Handi-Press) to form a pellet. Two mg of the NOCC paste was placed on top of the pellet and the combination was compressed again in the pellet holder. The portion of the pellet coated with the NOCC paste and the sides of the pellet were coated with the PVC resin. The pellet was then cured at 150C° for several minutes.

30

The resulting pellet was 7 mm in diameter and 2-3 mm thick and durable with some flexibility. The device contained 1% NOCC, and was adherent to moist tissue.

Example 6

The formulation described in Example 5 was modified by incorporating melatonin into the alginate paste component prior to pellet formation. The alginate paste was made 3.3% (w/w) melatonin, with the remaining ingredients having the same proportions. A pellet was then prepared as described in Example 5.

The resulting pellet contained 2 mg of melatonin and was of the same dimensions and physical properties as the device of Example 5. The formulation was adhesive to moist tissue. Using the same approach, pellets containing 4 mg of melatonin were also prepared.

Example 7

The formulation described in Example 5 was modified by incorporating chlorpheniramine maleate into the alginate paste component. The alginate paste was made 16.7% (w/w) chlorpheniramine maleate, with the remaining ingredients having the same proportions. A pellet was then prepared as described in Example 5.

The resulting pellet contained 10 mg of chlorpheniramine maleate and was of the same dimensions and physical properties as the device of Example 5. The formulation was adhesive to moist tissue. Using the same approach, pellets containing 5 mg of chlorpheniramine maleate were also prepared.

Example 8

In this example, a buccal device similar to that shown in Example 5 was prepared with an increased concentration of NOCC. The general methods and materials are similar to those shown in Example 5.

An alginate paste was prepared having the following composition:

52% sodium alginate
33% chitosan
15% PVC resin composition (as prepared in Example 5)
(All percentages are weight to weight.)

A NOCC paste was also prepared having the following composition:

50% NOCC
50% PVC resin composition (as prepared in Example 5)
(All percentages are weight to weight.)

5

The buccal device was prepared by compressing 70 mg of the alginate paste in a hand-held potassium bromide pellet press (Barnes Analytical, Pellet Holder for Handi-Press). Ten mg of the NOCC paste was placed on top of the pellet and the combination was compressed again in the pellet holder. The portion of the pellet coated with the NOCC paste and the sides of the pellet were coated with the PVC resin composition. The pellet was then cured at 150C° for several minutes.

The resulting pellet was 7 mm in diameter and 3-3.5 mm thick and durable with some flexibility. The device contained 6% NOCC. The formulation was adhesive to moist tissue.

Example 9

In this example, a different buccal device, one having NOCC throughout, was prepared.

20

A paste was prepared having the following composition:

50% sodium alginate
30% chitosan
4% NOCC
16% PVC resin composition (as prepared in Example 5)
(All percentages are weight to weight.)

25

The buccal device was prepared by compressing 100 mg of the paste in a hand-held potassium bromide pellet press (Barnes Analytical, Pellet Holder for Handi-Press). The end and sides of the pellet were coated with the PVC resin composition. The pellet was then cured at 150C° for several minutes.

The resulting pellet was 7 mm in diameter and 3-4 mm thick and durable with some flexibility. The device contained 4% NOCC throughout and was adhesive to moist tissue.

35

Example 10

In this example, a buccal device containing a liquid silicone rubber, rather than a heat-curable plastic, was manufactured.

5 A paste was prepared with the following composition:

42% sodium alginate
 16% chitosan
 10% NOCC
 10 32% Silastic® 7-6860 (Dow Corning)
 (All percentages are weight to weight.)

The buccal device was prepared by compressing 60 mg of the paste in a hand-held potassium bromide pellet press (Barnes Analytical, Pellet Holder for Handi-Press).
 15 A second 60 mg of the paste was placed on top of the pellet and the combination was compressed again in the pellet holder. The entire pellet was then coated with a diluted mixture of liquid silicone rubber (30% Silastic® Q7-4840 plus 70% hexanes). The pellet was then cured at 150C° for 20 minutes. The pellet was cleaved at the union between the portions of paste to yield two devices with one non-coated surface each.

20 The device was 7 mm in diameter and 2-3 mm thick; it was durable and somewhat flexible. The device contained 10% NOCC and was adhesive to moist tissue.

Example 11

25 In this example, the buccal devices from the previous examples were tested to determine the time of attachment of the device to the gingiva of test subjects. Table 4 shows the results of these experiments.

Table 4: Tests of Various Buccal Devices

30

Device	In vivo attachment time
Example 8.	32-41 hr
Example 9.	4 hr
Example 10.	13 hr

These results indicate that adhesive buccal devices incorporating NOCC can be prepared with different thermoplastics and thermoset rubbers. The attachment times can be altered by changing the composition or the method of preparation of the device.

5

Example 12

In this example, the permeation of levonorgestrel (LN) from the NOCC-based vaginal cream of Example 3, was determined.

Previously harvested pieces of rabbit large bowel (surface area 1.767 cm²) were
10 mounted in an Improved Franz Diffusion Cell containing 0.9% saline (13ml) as the receptor medium. The vaginal cream of Example 3 (1.0g) was applied directly to the rabbit tissue; the experiments were performed in triplicate.

Aliquots of 1.0ml (which were replaced with fresh saline solution) were
15 withdrawn from the receptor chamber at 1, 3, 6, 20, 24, 48 hours. LN in samples was quantified using high performance liquid chromatography (Hewlett Packard, model 1090, series II, fitted with Hypersil C₁₈, 5µm, 25cm x 4.6 mm column, a UV detector set at 241nm and an acetonitrile(80%)-water(20%) mobile phase).

20 Accurately weighed portions of the LN-vaginal cream as well as the cream recovered from the diffusion cells were extracted with 20ml methanol for 16hr on a wrist-action shaker and analyzed. The *in vitro* permeation profiles for the 3mg/g vaginal cream is shown in Figure 6. The profile demonstrates a near linear release with time over the 48 hr test period. The replicate results along with an average are plotted. The
25 permeation rate of hormone that diffused through the tissue from the cream was very small ($0.163 \pm 0.010 \mu\text{g}/\text{cm}^2/\text{hr}$).

Analysis of the vaginal cream formulation following methanol extraction found
2.964± 0.020 mg/g LN in the nominal 3mg/g cream. The concentration of LN in the
30 creams recovered following the permeation studies were 3.101±0.315mg/g for the 3mg/g cream. This confirmed that the bulk of the hormone was retained within the vaginal cream and not released through the tissue membrane.

Vaginal creams based on NOCC released very limited amounts (i.e. less than 0.5%) of levonorgestrel through normal tissue over a 48 hr period. This finding implies that such creams would maintain low levels of systemic hormones *in vivo* and would allow for the attachment of LN to steroid receptors on the surface of mucosal tissue (local effect). In addition, since these formulations are strongly adherent and insoluble at the acidity of the vagina, NOCC-based vaginal creams appear to be suitable candidates for vaginal delivery devices.

Example 13

This example tested the release of melatonin from one of the described buccal devices. The buccal devices containing 2 mg of melatonin described in Example 6 were placed directly onto pieces of previously harvested rabbit large bowel that were mounted in Franz Diffusion Cells as described in Example 12. The permeation studies were conducted as described in Example 12 except that the HPLC analysis was modified; a Spectra Physics, Model SP8800, fitted with Alltima phenyl, 5 micron, 15cm X 4.6 mm column, and a UV detector set at 223 nm was used with an acetonitrile (40%)- 0.1% phosphoric acid mobile phase.

The *in vitro* permeation profile is shown in Figure 7. The flux can be calculated from this graph by determining its slope. For the device or pellet containing 2mg of melatonin, the average permeation rate (flux) was $19.5 \mu\text{g}/\text{cm}^2/\text{hr}$. For the pellet containing 4 mg of melatonin, the flux was approximately the same as for the 2 mg pellet, indicating that even at 2 mg, the pellet is saturated with melatonin. The flux of $19.5 \mu\text{g}/\text{cm}^2/\text{hr}$ is adequate to produce a systemic therapeutic level of melatonin.

Example 14

In this example, the buccal devices of Example 7 were tested for permeation of chlorpheniramine maleate through mucosal membranes *in vitro*. Several buccal devices, containing chlorpheniramine maleate described in Example 7 were placed directly onto pieces of previously harvested rabbit large bowel that were mounted in Franz Diffusion Cells as described in Example 12. The permeation studies were conducted as described in Example 12 except that the HPLC analysis was modified: a Spectra Physics, Model SP8800, fitted with Alltima C8, 5 micron, 15cm X 4.6 mm column, and a UV detector

set at 261 nm with an acetonitrile (30%)- 0.05% potassium dihydrogen phosphate plus 1ml of phosphoric acid, pH 2.5 (70%) mobile phase.

The *in vitro* permeation profile is shown in Figure 8. The flux can be calculated from this graph by determining its slope. For the pellet containing 10 mg of chlorpheniramine maleate, the average permeation rate through the mucosal tissue was 182 $\mu\text{g}/\text{cm}^2/\text{hr}$. For a pellet containing 5 mg of the drug, the average permeation rate through the mucosal tissue was 97.3 $\mu\text{g}/\text{cm}^2/\text{hr}$. This value is approximately half of that for the pellet containing 10 mg of chlorpheniramine maleate, indicating that these buccal devices (pellets) are not saturated with the drug. The flux of 182 $\mu\text{g}/\text{cm}^2/\text{hr}$ is adequate to produce systemic therapeutic levels since the oral daily dosage for chlorpheniramine maleate is 2 mg.

Example 15

In this example, a dental device containing chlorhexidine diacetate was made. Silastic® (liquid silicone rubber: 7-6860) was obtained from Dow Corning. A paste was prepared with the following composition:

42% sodium alginate
16% chitosan
10% NOCC
32% Silastic® 7-6860
(All percentages are weight to weight.)

37.9 mg of chlorhexidine diacetate (Sigma Aldrich) was added to 410 mg of this paste with mixing. Chlorhexidine diacetate is a broad-spectrum anti-bacterial used for control of periodontal disease. Buccal-adhering devices were prepared as described in Example 10 using 60 mg portions of the mixture.

The device was 7 mm in diameter and 2-3 mm thick; it was durable and somewhat flexible. The device contained 9.15% NOCC and 5.08 mg of chlorhexidine diacetate and was adhesive to moist tissue.

Example 16

In this example, an eye delivery device containing timolol maleate was made. Timolol maleate is a beta-blocker used to reduce pressure in the eye.

5

A paste was prepared with the following composition:

- 42% sodium alginate
- 16% chitosan
- 10% NOCC
- 10 32% Silastic® 7-6860 (Dow Corning)
- (All percentages are weight to weight.)

19.7 mg of timolol maleate (Sigma Aldrich) was added to 243 mg of the paste (Sigma Aldrich) with mixing. Thin wafers were prepared using the press and techniques described in Example 10 but with 20 mg portions of the paste-drug mixture.

15

The device was 7 mm in diameter and less than 1 mm thick; it was durable and somewhat flexible. The device contained 9.25% NOCC and 1.50 mg of timolol maleate and was adhesive to moist tissue.

20

Example 17

This example tested the permeation from the buccal device of Example 15.

The buccal-adhering devices, containing 5 mg of chlorhexidine diacetate, described in Example 15 were placed directly onto pieces of previously harvested rabbit large bowel that were mounted in Franz Diffusion Cells as described in Example 12. The permeation studies were conducted as described in Example 12 except that the analysis of the receptor solution was performed using a UV-Visible Spectrophotometer (Pharmacia Biotech Ultraspec 2000, set at a wavelength of 230 nm) and 3.0ml aliquots were withdrawn at 0.5, 1, 2, 3, 4, 6, 18, and 24 hours.

25
30

The *in vitro* average (n=2) permeation profile is shown in Figure 9. The flux can be calculated from this graph by determining its slope. For the device or pellet

containing 5 mg of chlorhexidine diacetate, the average permeation rate through the mucosal tissue was 160.8 $\mu\text{g}/\text{cm}^2/\text{hr}$.

5 The flux of 160.8 $\mu\text{g}/\text{cm}^2/\text{hr}$ is adequate to produce a local therapeutic effect in local tissues. Hence, these devices are suitable for the delivery of drugs that are used to treat mouth sores and periodontal disease.

Example 18

10 This example shows the permeation from the eye drug delivery device made in Example 16.

15 The wafers, containing 1.50 mg of timolol maleate, described in Example 16 were placed directly onto pieces of previously harvested rabbit large bowel that were mounted in Franz Diffusion Cells as described in Example 12. The permeation studies were conducted as described in Example 12 except that the analysis of the receptor solution was performed using a UV-Visible Spectrophotometer (Pharmacia Biotech Ultraspec 2000, set at a wavelength of 295 nm) and 3.0ml aliquots were withdrawn at 0.5, 1, 2, 3, 4, 6, 18, and 24 hours.

20 The *in vitro* average (n=2) permeation profile is shown in Figure 10. The flux can be calculated from this graph by determining its slope. For the device or pellet containing 1.50 mg of timolol maleate, the average permeation rate through the mucosal tissue was 103.8 $\mu\text{g}/\text{cm}^2/\text{hr}$.

25 The flux of 103.8 $\mu\text{g}/\text{cm}^2/\text{hr}$ is adequate to produce a therapeutic effect to treat glaucoma when the wafer is inserted between the eye and eye lid. Hence, these devices are suitable for the delivery of drugs (such as beta blockers) to the eye.

Example 19

In this example, an adherent formulation containing a fibrin sealant for prevention of surgical adhesions was prepared. A commercial 2-component fibrin sealant kit (Tisseel® Kit, Baxter Hyland Immuno) was used following the manufacturer's directions with one exception. The vial of protein concentrate (containing fibrinogen) was divided into portions that were reconstituted with either saline or NOCC solution (1.25% w/v). Thrombin was used at a level of 4 IU/ml for "slow solidification" according to the manufacturer's directions. The fibrin sealant with and without NOCC was applied to pieces of rabbit large bowel tissue. The tissues with sealant were cured for several minutes at 35-37C° and inspected.

Within a few minutes the two different sealants had set and were no longer fluid. Both sealant mixtures adhered well to the underlying tissue. The sealant that incorporated NOCC was more viscous and remained in place better than the thinner, non-NOCC sealant that tended to flow away from the site of placement. The presence of NOCC slowed the setting time of the gel and yielded a more flexible material initially. The sealants covered the site of placement well and were no longer sticky on the exposed surface once they had cured.

Hence, the NOCC-containing sealant provides an improved adhesion barrier that remains at the site of application and forms a more flexible layer.

Example 20

In this example, an adherent formulation containing a fibrin sealant for sealing or attaching tissues was prepared. A two component commercial fibrin sealant kit (Tisseel® Kit, Baxter Hyland Immuno) was used to test for an adherent formulation with NOCC. The vial of protein concentrate (containing fibrinogen) was divided into portions that were reconstituted at 35C° with either saline or NOCC solution (1.25% w/v). Freeze-dried thrombin was reconstituted with saline to yield a solution containing 13.9 IU/ml. Two ml of the thrombin solution was mixed with 2 ml of 10 mg/ml calcium chloride solution.

Fibrin sealant with and without NOCC was applied to rabbit large bowel tissue using the mixing dispenser supplied by the manufacturer. The tissues were approximately 1 inch square and the sealant was applied to half of the tissue. Immediately following the application of the sealant, the tissue was folded onto itself
5 and pressed together lightly for 10-20 seconds. The tissues were kept warm (35-37C°) for 30 minutes and then evaluated.

In both cases, the tissues were firmly sealed together. There was more of the sealant containing NOCC within the folded tissue. The sealant that incorporated NOCC
10 was more viscous and remained in place while the thinner non-NOCC sealant tended to flow away from the site of placement. The effort required to pull the folded tissue apart was somewhat greater for the NOCC containing sealant.

Hence, combining NOCC with other sealants forms improved products that
15 effectively attach or seal tissues.

The foregoing examples are merely exemplary and those skilled in the art will be able to determine other modifications to the described procedures that fall within the scope of the invention. Accordingly, the invention is defined by the following claims
20 and equivalents thereof.

Claims

What is claimed is:

1. A method of providing sustained release of a drug to moist tissue
5 comprising applying to said moist tissue a drug delivery device which is adherent to said moist tissue and includes a level of N,O-carboxymethylchitosan as a component thereof to provide said adherence, said drug delivery device further containing a sufficient quantity of the drug to be delivered to provide sustained release of said drug and permeation into said moist tissue or into the surrounding cavity.
- 10 2. The method of claim 1, wherein said moist tissue comprises mucosal tissue.
- 15 3. The method of claim 2 wherein said mucosal tissue comprises tissue of the oral cavity.
- 20 4. The method of claim 3 wherein said oral cavity tissue comprises buccal tissue.
- 25 5. The method of claim 4 wherein said drug is selected from the group consisting of melatonin, chlorpheniramine, chlorhexidine, tetracycline and mixtures thereof.
6. The method of claim 4 wherein said drug delivery device is used to treat a condition selected from the group consisting of mouth sores and periodontal disease.
7. The method of claim 4 wherein said drug delivery device is used to deliver a systemic therapeutic effect.
- 30 8. The method of claim 3 wherein said device comprises a structural support material selected from the group consisting of rubber, plastic, resin, natural and synthetic polymers, and mixtures thereof.
- 35 9. The method of claim 2 wherein said mucosal tissue comprises vaginal tissue.

10. The method of claim 9 wherein said drug is selected from a group consisting of progestins, estrogens, antifungal agents, antibacterial agents, anti-viral agents, proteins and peptides.

5 11. The method of claim 10 wherein said drug comprises levonorgestrel.

12. The method of claim 2 wherein said mucosal tissue comprises ocular tissue.

10 13. The method of claim 12 wherein said drug is selected from the group consisting of beta blockers and glaucoma treating drugs.

15 14. The method of claim 2 wherein said mucosal tissue comprises the gastrointestinal tract.

15 15. The method of claim 1 wherein said moist tissue is tissue in a serous cavity.

20 16. The method of claim 15 wherein said moist tissue is tissue within the pleural, pericardial or peritoneal cavities.

17. The method of claim 1 wherein said moist tissue comprises bone.

25 ~~18.~~ A method of adhering moist tissue together comprising the steps of applying a medical device which is adherent to said moist tissue and can effect such adherence, said medical device containing N,O-carboxymethylchitosan as a component thereof.

30 19. The method of claim 18 wherein said medical device further comprises a tissue sealant.

20. The method of claim 18 wherein said moist tissue is at the site of a surgical incision.

35 21. The method of claim 19 wherein said tissue sealant comprises a fibrin glue.

22. The method of claim 19 wherein said tissue sealant comprises a cyanoacrylate.

23. The method of claim 19 wherein said tissues to be sealed are selected
5 from the group consisting of lung tissues, heart tissues and intestinal tissue.

24. The method of claim 18 wherein said tissue adhered together comprises a defect in said moist tissue.

10 ~~25.~~ A method of preventing surgical adhesions in moist tissue comprising the steps of applying a medical device which is adherent to said moist tissue and can effect such adherence, said medical device containing N,O-carboxymethylchitosan as a component thereof, said medical device further comprising a surgical adhesion barrier.

15 26. The method of claim 24 wherein said surgical adhesion barrier comprises a fibrin glue.

Abstract Of The Disclosure

The present invention relates to drug delivery devices for moist tissue, in particular mucosal tissue and tissue in the serous cavities, as well as a method of its use. The devices, which contain NOCC, are adherent to the mucosal tissue, allowing
5 localized drug delivery. The devices are particularly useful in vaginal, buccal and ocular devices.

009020 070600 090304 090304




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5

LEVONORGESTREL VAGINAL CREAM DELIVERY SYSTEM (3 mg/g)
IN VITRO PERMEATION THROUGH BIOLOGICAL MEMBRANE




FIG. 6

MELATONIN BUCCAL DELIVERY SYSTEM - IN VITRO PERMEATION THROUGH BIOLOGICAL
MEMBRANE




FIG. 7

CHLORPHENIRAMINE MALEATE BUCCAL DELIVERY SYSTEM - IN VITRO PERMEATION
THROUGH BIOLOGICAL MEMBRANE




FIG. 8

09540281.070500




FIG. 9

Timolol Maleate - Eye Delivery System on Biological Membrane




FIG. 10

**DECLARATION, PETITION AND POWER OF ATTORNEY FOR
CONTINUATION-IN-PART PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**ADHERENT N,O- CARBOXYMETHYLCHITOSAN DRUG DELIVERY DEVICES
FOR MOIST TISSUE AND METHODS OF THEIR USE**

the specification of which

- ☒ attached hereto;
- ☐ was filed on _____ as Application Serial No. _____; and
- ☐ was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

This application in part discloses and claims subject matter disclosed in my earlier filed application(s), as follows:

- ☒ Serial No. 09/315,480, filed May 20, 2000;
as to which I claim priority benefit under Title 35, United States Code, §120.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56, including all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of the continuation-in-part application.

AS TO PARENT APPLICATION

As to the subject matter of this application which is common to said earlier application, I do not know and do not believe that the same was ever known or used in the United States of America before my or our invention thereof or patented or described in any printed publication in any country before my or our invention thereof, or more than one year prior to said earlier application, or in public use or on sale in the United States of America more than one year prior to said earlier application; that the common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to said earlier application; and

As to applications for patents or inventor's certificate or PCT international application(s) designating at least one country other than the United States of America, on the common subject matter, filed in or designating any country foreign to the United States of America, prior to said earlier application by me or my legal representatives or assigns,

- ☒ no such applications have been filed.
- ☐ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID EARLIER U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

AS TO THIS APPLICATION

As to the subject matter of this application which is common to said earlier application, I do not know and do not believe that the same was ever known or used in the United States of America before my or our invention thereof or patented or described in any printed publication in any country before my or our invention thereof, or more than one year prior to said earlier application, or in public use or on sale in the United States of America more than one year prior to said earlier application; that the common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to said earlier application; and

As to applications for patents or inventor's certificate or PCT international application(s) designating at least one country other than the United States of America, on the common subject matter, filed in or designating any country foreign to the United States of America, prior to said earlier application by me or my legal representatives or assigns,

- ☒ no such applications have been filed.
- ☐ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID EARLIER U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

CLAIM FOR BENEFIT OF U.S. PROVISIONAL APPLICATION(S)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

CLAIM FOR BENEFIT OF U.S. PATENT APPLICATION(S)

I hereby claim the benefit under 35 U.S.C. §120 of any United States patent application(s) listed below.

09/315,480

(Application Serial No.)

May 20, 1999

(Filing Date)

(Application Serial No.)

(Filing Date)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

James E. Cockfield	Reg. No. 19,162	Megan E. Williams	Reg. No. 43,270
Thomas V. Smurzynski	Reg. No. 24,798	Nicholas P. Triano III	Reg. No. 36,397
Ralph A. Loren	Reg. No. 29,325	Peter C. Lauro	Reg. No. 32,360
Giulio A. DeConti, Jr.	Reg. No. 31,503	DeAnn F. Smith	Reg. No. 36,683
Ann Lamport Hammitte	Reg. No. 34,858	William D. DeVaul	Reg. No. 42,483
Elizabeth A. Hanley	Reg. No. 33,505	David J. Ridders	Reg. No. 43,882
Amy E. Mandragouras	Reg. No. 36,207	Chi Suk Kim	Reg. No. 42,728
Anthony A. Laurentano	Reg. No. 38,220	Maria Laccotripe Zacharakis	Limited Recognition Under 37 C.F.R. § 10.9(b)
Jane E. Remillard	Reg. No. 38,872	Debra J. Milasincic	Reg. No. P46,931
Jeremiah Lynch	Reg. No. 17,425	David R. Burns	Reg. No. P46,590
Kevin J. Canning	Reg. No. 35,470		
David A. Lane, Jr.	Reg. No. 39,261		
Jeanne M. DiGiorgio	Reg. No. 41,710		

all of: **Lahive & Cockfield, LLP**, 28 State Street, Boston, MA 02109
United States of America

Send Correspondence to **Ralph A. Loren, Esq. at Customer Number 000959** whose address is:

of: **Lahive & Cockfield, LLP**, 28 State Street, Boston, MA 02109
United States of America

Direct telephone calls to **Ralph A. Loren, Esq. at (617) 227-7400**.

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Clive M. Elson	
Inventor's signature	Date
Residence 84 Anchor Drive, Halifax, Nova Scotia, B3N 3E1 CANADA	
Citizenship CANADA	
Post Office Address (if different)	

Full name of second inventor, if any Agis Kydonieus	
Inventor's signature	Date
Residence 17 Savage Road, Kendell Park, New Jersey 08824	
Citizenship UNITED STATES	
Post Office Address (if different)	